Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Bézard E[au]:

Search results

Items: 1 to 50 of 283

1.

Multiple System Atrophy: Recent Developments and Future Perspectives.

Meissner WG, Fernagut PO, Dehay B, Péran P, Traon AP, Foubert-Samier A, Lopez Cuina M, Bezard E, Tison F, Rascol O.

Mov Disord. 2019 Nov 6. doi: 10.1002/mds.27894. [Epub ahead of print] Review.

PMID:
31692132
2.

Intrastriatal injection of alpha-synuclein fibrils induces Parkinson-like pathology in macaques.

Dehay B, Bezard E.

Brain. 2019 Nov 1;142(11):3321-3322. doi: 10.1093/brain/awz329. No abstract available.

PMID:
31665750
3.

Managing Parkinson's disease: Moving ON with NOP.

Mercatelli D, Bezard E, Eleopra R, Zaveri NT, Morari M.

Br J Pharmacol. 2019 Oct 24. doi: 10.1111/bph.14893. [Epub ahead of print] Review.

PMID:
31648371
4.

Comprehensive mapping of neurotransmitter networks by MALDI-MS imaging.

Shariatgorji M, Nilsson A, Fridjonsdottir E, Vallianatou T, Källback P, Katan L, Sävmarker J, Mantas I, Zhang X, Bezard E, Svenningsson P, Odell LR, Andrén PE.

Nat Methods. 2019 Oct;16(10):1021-1028. doi: 10.1038/s41592-019-0551-3. Epub 2019 Sep 23.

PMID:
31548706
5.

Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies.

Arotcarena ML, Bourdenx M, Dutheil N, Thiolat ML, Doudnikoff E, Dovero S, Ballabio A, Fernagut PO, Meissner WG, Bezard E, Dehay B.

JCI Insight. 2019 Aug 22;4(16). pii: 129719. doi: 10.1172/jci.insight.129719.

6.

Dystonia and dopamine: From phenomenology to pathophysiology.

Ribot B, Aupy J, Vidailhet M, Mazère J, Pisani A, Bezard E, Guehl D, Burbaud P.

Prog Neurobiol. 2019 Nov;182:101678. doi: 10.1016/j.pneurobio.2019.101678. Epub 2019 Aug 9. Review.

7.

Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson's disease.

Rosenblad C, Li Q, Pioli EY, Dovero S, Antunes AS, Agúndez L, Bardelli M, Linden RM, Henckaerts E, Björklund A, Bezard E, Björklund T.

Brain. 2019 Aug 1;142(8):2402-2416. doi: 10.1093/brain/awz176.

8.

The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson's disease patients.

Nuzzo T, Punzo D, Devoto P, Rosini E, Paciotti S, Sacchi S, Li Q, Thiolat ML, Véga C, Carella M, Carta M, Gardoni F, Calabresi P, Pollegioni L, Bezard E, Parnetti L, Errico F, Usiello A.

Sci Rep. 2019 Jun 20;9(1):8898. doi: 10.1038/s41598-019-45419-1.

9.

Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson's disease.

Delamarre A, Tison F, Li Q, Galitzky M, Rascol O, Bezard E, Meissner WG.

J Neural Transm (Vienna). 2019 Jun;126(6):789-793. doi: 10.1007/s00702-019-02015-x. Epub 2019 May 16.

PMID:
31098725
10.

l-Dopa-free learned dyskinetic behavior in a Parkinson's primate model.

Li Q, Fernagut PO, Bezard E.

Mov Disord. 2019 Aug;34(8):1237. doi: 10.1002/mds.27715. Epub 2019 May 13. No abstract available.

PMID:
31083822
11.

Engrailed-1 induces long-lasting behavior benefit in an experimental Parkinson primate model.

Thomasson N, Pioli E, Friedel C, Monseur A, Lavaur J, Moya KL, Bezard E, Bousseau A, Prochiantz A.

Mov Disord. 2019 Jul;34(7):1082-1084. doi: 10.1002/mds.27714. Epub 2019 May 11. No abstract available.

PMID:
31077447
12.

Local transgene expression and whole-body transgenesis to model brain diseases in nonhuman primate.

Chansel-Debordeaux L, Bezard E.

Animal Model Exp Med. 2019 Jan 29;2(1):9-17. doi: 10.1002/ame2.12055. eCollection 2019 Mar. Review.

13.

Remnants of Cardinal Symptoms of Parkinson's Disease, Not Dyskinesia, Are Problematic for Dyskinetic Patients Performing Activities of Daily Living.

Goubault E, Nguyen HP, Bogard S, Blanchet PJ, Bézard E, Vincent C, Sarna J, Monchi O, Duval C.

Front Neurol. 2019 Mar 22;10:256. doi: 10.3389/fneur.2019.00256. eCollection 2019.

14.

Microdialysis in awake macaque monkeys for central nervous system pharmacokinetics.

Thiollier T, Wu C, Porras G, Bezard E, Li Q, Zhang J, Contamin H.

Animal Model Exp Med. 2018 Dec 4;1(4):314-321. doi: 10.1002/ame2.12046. eCollection 2018 Dec.

15.

Nanoscale exploration of the extracellular space in the live brain by combining single carbon nanotube tracking and super-resolution imaging analysis.

Paviolo C, Soria FN, Ferreira JS, Lee A, Groc L, Bezard E, Cognet L.

Methods. 2019 Mar 9. pii: S1046-2023(18)30451-1. doi: 10.1016/j.ymeth.2019.03.005. [Epub ahead of print]

PMID:
30862507
16.

TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates.

Laferrière F, Maniecka Z, Pérez-Berlanga M, Hruska-Plochan M, Gilhespy L, Hock EM, Wagner U, Afroz T, Boersema PJ, Barmettler G, Foti SC, Asi YT, Isaacs AM, Al-Amoudi A, Lewis A, Stahlberg H, Ravits J, De Giorgi F, Ichas F, Bezard E, Picotti P, Lashley T, Polymenidou M.

Nat Neurosci. 2019 Jan;22(1):65-77. doi: 10.1038/s41593-018-0294-y. Epub 2018 Dec 17.

PMID:
30559480
17.

RGS9-2 rescues dopamine D2 receptor levels and signaling in DYT1 dystonia mouse models.

Bonsi P, Ponterio G, Vanni V, Tassone A, Sciamanna G, Migliarini S, Martella G, Meringolo M, Dehay B, Doudnikoff E, Zachariou V, Goodchild RE, Mercuri NB, D'Amelio M, Pasqualetti M, Bezard E, Pisani A.

EMBO Mol Med. 2019 Jan;11(1). pii: e9283. doi: 10.15252/emmm.201809283.

18.

Harnessing Lysosomal pH through PLGA Nanoemulsion as a Treatment of Lysosomal-Related Neurodegenerative Diseases.

Prévot G, Soria FN, Thiolat ML, Daniel J, Verlhac JB, Blanchard-Desce M, Bezard E, Barthélémy P, Crauste-Manciet S, Dehay B.

Bioconjug Chem. 2018 Dec 19;29(12):4083-4089. doi: 10.1021/acs.bioconjchem.8b00697. Epub 2018 Nov 27.

PMID:
30424597
19.

The hidden side of Parkinson's disease: Studying pain, anxiety and depression in animal models.

Faivre F, Joshi A, Bezard E, Barrot M.

Neurosci Biobehav Rev. 2019 Jan;96:335-352. doi: 10.1016/j.neubiorev.2018.10.004. Epub 2018 Oct 23. Review.

PMID:
30365972
20.

Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts.

Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH, Bezard E, Picconi B, Calabresi P, Lang AE.

Ann Neurol. 2018 Dec;84(6):797-811. doi: 10.1002/ana.25364. Epub 2018 Nov 30. Review.

PMID:
30357892
21.

Meta-analysis of amantadine efficacy for improving preclinical research reliability.

Stanley P, Pioli EY, Kozak R, Popiolek M, Bezard E.

Mov Disord. 2018 Oct;33(10):1555-1557. doi: 10.1002/mds.27486. Epub 2018 Oct 4. No abstract available.

PMID:
30288778
22.

NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology.

Mellone M, Zianni E, Stanic J, Campanelli F, Marino G, Ghiglieri V, Longhi A, Thiolat ML, Li Q, Calabresi P, Bezard E, Picconi B, Di Luca M, Gardoni F.

Neurobiol Dis. 2019 Jan;121:338-349. doi: 10.1016/j.nbd.2018.09.021. Epub 2018 Sep 24.

PMID:
30261285
23.

An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates.

Charvin D, Di Paolo T, Bezard E, Gregoire L, Takano A, Duvey G, Pioli E, Halldin C, Medori R, Conquet F.

Mov Disord. 2018 Oct;33(10):1619-1631. doi: 10.1002/mds.27462. Epub 2018 Sep 14.

PMID:
30216534
24.

Configuration of electrical spinal cord stimulation through real-time processing of gait kinematics.

Capogrosso M, Wagner FB, Gandar J, Moraud EM, Wenger N, Milekovic T, Shkorbatova P, Pavlova N, Musienko P, Bezard E, Bloch J, Courtine G.

Nat Protoc. 2018 Sep;13(9):2031-2061. doi: 10.1038/s41596-018-0030-9.

PMID:
30190556
25.

G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice.

Novello S, Arcuri L, Dovero S, Dutheil N, Shimshek DR, Bezard E, Morari M.

Neurobiol Dis. 2018 Dec;120:21-33. doi: 10.1016/j.nbd.2018.08.018. Epub 2018 Aug 30.

PMID:
30172844
26.

Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing.

Boland B, Yu WH, Corti O, Mollereau B, Henriques A, Bezard E, Pastores GM, Rubinsztein DC, Nixon RA, Duchen MR, Mallucci GR, Kroemer G, Levine B, Eskelinen EL, Mochel F, Spedding M, Louis C, Martin OR, Millan MJ.

Nat Rev Drug Discov. 2018 Sep;17(9):660-688. doi: 10.1038/nrd.2018.109. Epub 2018 Aug 17. Review.

27.

Systemic Gene Delivery by Single-Dose Intracardiac Administration of scAAV2/9 and scAAV2/rh10 Variants in Newborn Rats.

Chansel-Debordeaux L, Bourdenx M, Dutheil N, Dovero S, Canron MH, Jimenez C, Bezard E, Dehay B.

Hum Gene Ther Methods. 2018 Aug;29(4):189-199. doi: 10.1089/hgtb.2017.192.r3.

PMID:
30064266
28.

The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia.

Rojo-Bustamante E, Abellanas MA, Clavero P, Thiolat ML, Li Q, Luquin MR, Bezard E, Aymerich MS.

Neurobiol Dis. 2018 Oct;118:64-75. doi: 10.1016/j.nbd.2018.06.019. Epub 2018 Jun 21.

PMID:
29936234
29.

Cardinal Motor Features of Parkinson's Disease Coexist with Peak-Dose Choreic-Type Drug-Induced Dyskinesia.

Goubault E, Nguyen HP, Bogard S, Blanchet PJ, Bézard E, Vincent C, Langlois M, Duval C.

J Parkinsons Dis. 2018;8(2):323-331. doi: 10.3233/JPD-181312.

30.

Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.

Baufreton J, Milekovic T, Li Q, McGuire S, Moraud EM, Porras G, Sun S, Ko WKD, Chazalon M, Morin S, Normand E, Farjot G, Milet A, Pype J, Pioli E, Courtine G, Bessière B, Bezard E.

Mov Disord. 2018 Oct;33(10):1632-1642. doi: 10.1002/mds.27404. Epub 2018 May 14.

31.

The Tyrosine Phosphatase STEP Is Involved in Age-Related Memory Decline.

Castonguay D, Dufort-Gervais J, Ménard C, Chatterjee M, Quirion R, Bontempi B, Schneider JS, Arnsten AFT, Nairn AC, Norris CM, Ferland G, Bézard E, Gaudreau P, Lombroso PJ, Brouillette J.

Curr Biol. 2018 Apr 2;28(7):1079-1089.e4. doi: 10.1016/j.cub.2018.02.047. Epub 2018 Mar 22.

32.

Pharmacological Inhibition of Necroptosis Protects from Dopaminergic Neuronal Cell Death in Parkinson's Disease Models.

Iannielli A, Bido S, Folladori L, Segnali A, Cancellieri C, Maresca A, Massimino L, Rubio A, Morabito G, Caporali L, Tagliavini F, Musumeci O, Gregato G, Bezard E, Carelli V, Tiranti V, Broccoli V.

Cell Rep. 2018 Feb 20;22(8):2066-2079. doi: 10.1016/j.celrep.2018.01.089.

33.

Synaptic Regulator α-Synuclein in Dopaminergic Fibers Is Essentially Required for the Maintenance of Subependymal Neural Stem Cells.

Perez-Villalba A, Sirerol-Piquer MS, Belenguer G, Soriano-Cantón R, Muñoz-Manchado AB, Villadiego J, Alarcón-Arís D, Soria FN, Dehay B, Bezard E, Vila M, Bortolozzi A, Toledo-Aral JJ, Pérez-Sánchez F, Fariñas I.

J Neurosci. 2018 Jan 24;38(4):814-825. doi: 10.1523/JNEUROSCI.2276-17.2017. Epub 2017 Dec 7.

34.

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, Burn D, Halliday GM, Bezard E, Przedborski S, Lehericy S, Brooks DJ, Rothwell JC, Hallett M, DeLong MR, Marras C, Tanner CM, Ross GW, Langston JW, Klein C, Bonifati V, Jankovic J, Lozano AM, Deuschl G, Bergman H, Tolosa E, Rodriguez-Violante M, Fahn S, Postuma RB, Berg D, Marek K, Standaert DG, Surmeier DJ, Olanow CW, Kordower JH, Calabresi P, Schapira AHV, Stoessl AJ.

Mov Disord. 2017 Sep;32(9):1264-1310. doi: 10.1002/mds.27115. Review.

35.

In utero delivery of rAAV2/9 induces neuronal expression of the transgene in the brain: towards new models of Parkinson's disease.

Chansel-Debordeaux L, Bourdenx M, Dovero S, Grouthier V, Dutheil N, Espana A, Groc L, Jimenez C, Bezard E, Dehay B.

Gene Ther. 2017 Dec;24(12):801-809. doi: 10.1038/gt.2017.84. Epub 2017 Nov 16.

PMID:
28853717
36.

Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias.

Stanic J, Mellone M, Napolitano F, Racca C, Zianni E, Minocci D, Ghiglieri V, Thiolat ML, Li Q, Longhi A, De Rosa A, Picconi B, Bezard E, Calabresi P, Di Luca M, Usiello A, Gardoni F.

Neurobiol Dis. 2017 Dec;108:54-64. doi: 10.1016/j.nbd.2017.08.001. Epub 2017 Aug 18.

37.

Mitochondrial division inhibitor-1 is neuroprotective in the A53T-α-synuclein rat model of Parkinson's disease.

Bido S, Soria FN, Fan RZ, Bezard E, Tieu K.

Sci Rep. 2017 Aug 8;7(1):7495. doi: 10.1038/s41598-017-07181-0.

38.

Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to α-synuclein targeted disease modification.

Ko WKD, Bezard E.

Exp Neurol. 2017 Dec;298(Pt B):172-179. doi: 10.1016/j.expneurol.2017.07.020. Epub 2017 Jul 29. Review.

PMID:
28764902
39.

Decreased Rhes mRNA levels in the brain of patients with Parkinson's disease and MPTP-treated macaques.

Napolitano F, Booth Warren E, Migliarini S, Punzo D, Errico F, Li Q, Thiolat ML, Vescovi AL, Calabresi P, Bezard E, Morelli M, Konradi C, Pasqualetti M, Usiello A.

PLoS One. 2017 Jul 25;12(7):e0181677. doi: 10.1371/journal.pone.0181677. eCollection 2017.

40.

A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.

Ko WKD, Li Q, Cheng LY, Morelli M, Carta M, Bezard E.

Eur J Pharmacol. 2017 Oct 15;813:10-16. doi: 10.1016/j.ejphar.2017.07.030. Epub 2017 Jul 21.

PMID:
28739086
41.

Alterations in Functional Cortical Hierarchy in Hemiparkinsonian Rats.

Jávor-Duray BN, Vinck M, van der Roest M, Bezard E, Berendse HW, Boraud T, Voorn P.

J Neurosci. 2017 Aug 9;37(32):7669-7681. doi: 10.1523/JNEUROSCI.3257-16.2017. Epub 2017 Jul 7.

42.

Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy.

Bassil F, Guerin PA, Dutheil N, Li Q, Klugmann M, Meissner WG, Bezard E, Fernagut PO.

Mov Disord. 2017 Aug;32(8):1230-1239. doi: 10.1002/mds.27041. Epub 2017 May 29.

PMID:
28556404
43.

Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia.

Bastide MF, Glangetas C, Doudnikoff E, Li Q, Bourdenx M, Fernagut PO, Dumont ÉC, Georges F, Bézard E.

Sci Rep. 2017 May 24;7(1):2348. doi: 10.1038/s41598-017-02572-9.

44.

Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration.

Soria FN, Engeln M, Martinez-Vicente M, Glangetas C, López-González MJ, Dovero S, Dehay B, Normand E, Vila M, Favereaux A, Georges F, Lo Bianco C, Bezard E, Fernagut PO.

Hum Mol Genet. 2017 Jul 15;26(14):2603-2615. doi: 10.1093/hmg/ddx120.

PMID:
28520872
45.

In vitro α-synuclein neurotoxicity and spreading among neurons and astrocytes using Lewy body extracts from Parkinson disease brains.

Cavaliere F, Cerf L, Dehay B, Ramos-Gonzalez P, De Giorgi F, Bourdenx M, Bessede A, Obeso JA, Matute C, Ichas F, Bezard E.

Neurobiol Dis. 2017 Jul;103:101-112. doi: 10.1016/j.nbd.2017.04.011. Epub 2017 Apr 11.

PMID:
28411117
46.

U18666A, an activator of sterol regulatory element binding protein pathway, modulates presynaptic dopaminergic phenotype of SH-SY5Y neuroblastoma cells.

Schmitt M, Dehay B, Bezard E, Garcia-Ladona FJ.

Synapse. 2017 Sep;71(9). doi: 10.1002/syn.21980. Epub 2017 Jun 20.

PMID:
28407359
47.

Lack of spontaneous age-related brain pathology in Octodon degus: a reappraisal of the model.

Bourdenx M, Dovero S, Thiolat ML, Bezard E, Dehay B.

Sci Rep. 2017 Apr 4;7:45831. doi: 10.1038/srep45831.

48.

Insulin resistance and exendin-4 treatment for multiple system atrophy.

Bassil F, Canron MH, Vital A, Bezard E, Li Y, Greig NH, Gulyani S, Kapogiannis D, Fernagut PO, Meissner WG.

Brain. 2017 May 1;140(5):1420-1436. doi: 10.1093/brain/awx044.

49.

Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate.

Migdalska-Richards A, Ko WKD, Li Q, Bezard E, Schapira AHV.

Synapse. 2017 Jul;71(7). doi: 10.1002/syn.21967. Epub 2017 Mar 17.

50.

Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update.

Voon V, Napier TC, Frank MJ, Sgambato-Faure V, Grace AA, Rodriguez-Oroz M, Obeso J, Bezard E, Fernagut PO.

Lancet Neurol. 2017 Mar;16(3):238-250. doi: 10.1016/S1474-4422(17)30004-2. Epub 2017 Feb 15. Review.

PMID:
28229895

Supplemental Content

Loading ...
Support Center